Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
June 03 2021 - 6:05AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF
FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2021
Commission File Number: 001-40212
Connect Biopharma Holdings Limited
(Translation of registrants name into English)
Science and
Technology Park
East R&D Building, 3rd Floor
6 Beijing West Road, Taicang
Jiangsu Province, China 215400
(Address of principal executive office)
Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
On May 25, 2021, Connect Biopharma Holdings Limited (the Company) issued the press release
attached hereto as Exhibit 99.1, which is incorporated herein by reference.
On June 2, 2021, spokespersons of the Company presented the information
in the presentation slides attached hereto as Exhibit 99.2 in a previously announced webcast. The Company posted the updated corporate presentation to the Companys website, www.connectbiopharm.com. The Company plans to use its website to
disseminate future updates to its corporate presentation and does not intend to furnish a Form 6-K alerting investors each time the presentation is updated.
The furnishing of the attached presentation is not an admission as to the materiality of any information therein. The information contained in the
presentation is summary information that is intended to be considered in the context of more complete information included in the Companys filings with the Securities and Exchange Commission (the SEC) and other public announcements
that the Company has made and may make from time to time. The Company undertakes no duty or obligation to update or revise the information contained in this report, although it may do so from time to time as its management believes is appropriate.
Any such updating may be made through the filing or furnishing of other reports or documents with the SEC or through other public disclosures.
Exhibit Index
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
|
|
|
|
|
|
Dated: June 3, 2021
|
|
|
|
|
|
CONNECT BIOPHARMA HOLDINGS LIMITED
|
|
|
|
|
|
|
|
|
By
|
|
/s/ Eric Hall
|
|
|
|
|
Name:
|
|
Eric Hall
|
|
|
|
|
Title:
|
|
Interim Chief Financial Officer
|
Connect Biopharma (NASDAQ:CNTB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Connect Biopharma (NASDAQ:CNTB)
Historical Stock Chart
From Apr 2023 to Apr 2024